Collision of Alzheimers disease and COVID-19 pandemic in the United States: risks, outcomes, disparities and treatments

美国阿尔茨海默病和 COVID-19 大流行的碰撞：风险、结果、差异和治疗

• 批准号: 10417884
• 负责人: Pamela B Davis
• 金额: $ 234.2万
• 依托单位: CASE WESTERN RESERVE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-05-01 至 2025-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10417884
• 关键词: 2019-nCoV; African American population; Age; Alzheimer' s Disease; Alzheimer' s disease related dementia; American; Americas; COVID-19; COVID-19 pandemic; COVID-19 risk; COVID-19 survivors; Categories; Clinical Trials; Communicable Diseases; Complex; Contracts; Data; Databases; Development; Diagnosis; Direct Costs; Disease; Electronic Health Record; Elements; Etiology; Evolution; Facilities and Administrative Costs; Family Caregiver; Future; Hand; Health Policy; Healthcare Systems; Hispanic Populations; Incidence; Inflammation; Investigation; Knowledge; Mass Vaccinations; Methods; Nature; Outcome; Patients; Post-Acute Sequelae of SARS-CoV-2 Infection; Public Health; Risk; SARS-CoV-2 infection; Survivors; TNF gene; Testing; Therapeutic; Therapeutic Effect; Time; United States; Update; Variant; Virus Diseases; Woman; aging population; base; disorder prevention; experimental study; gender disparity; improved; inhibitor; insight; mortality; neuroinflammation; neuropsychiatric sequelae of COVID-19; neuropsychiatry; older patient; pandemic disease; patient population; racial disparity; real time monitoring; response

PROJECT SUMMARY In this project titled “Collision of Alzheimer’s disease and COVID-19 pandemic in the United States: risks, outcomes, disparities and treatments”, we propose to: 1) examine COVID-19 risk in patients with Alzheimer’s disease (AD), consider racial and gender disparity, and follow its evolution over time; 2) examine new onset of AD in COVID-19 survivors, consider racial and gender disparity, and follow these changes over time; 3) characterize long-haul neuropsychiatric Post-Acute Sequelae of COVID-19 (Neuro-PASC) in COVID- 19 survivors with AD, consider racial and gender disparity, and follow these changes over time; and 4) investigate therapeutic effects of Tumor Necrosis Factor (TNF) blockers on overall mortality and long-haul Neuro-PASC in COVID-19 survivors with AD. To answer these questions, we will utilize a US nation-wide, real- time database of de-identified electronic health records (EHRs) of 80 million patients (4.8 million confirmed COVID-19 cases). Our study will primarily focus on over 17 million senior patients age ³ 65 years, including more than 1 million COVID-19 cases, 265,818 patients diagnosed with AD, and 22,518 patients with both COVID-19 and AD (as of May 20, 2021). Our study will establish methods for real-time analysis of EHRs of vulnerable aging population of tens of millions across the USA in examining infectious diseases and their interaction with existing disorders such as AD, which will allow us to be better prepared should another pandemic overtake us. The significance of these studies therefore extends beyond the data at hand.

项目摘要 在该项目中，标题为“美国阿尔茨海默氏病和19日大流行的碰撞： 风险，结果，差异和治疗”，我们建议：1）检查 阿尔茨海默氏病（AD），考虑种族和性别差异，并随着时间的流逝而遵循其进化； 2）检查 Covid-19-19幸存者的广告新发作，考虑种族和性别差异，并遵循这些变化 时间; 3）表征covid-19（neuro-pasc）在covid-中的长途神经精神疾病后急性后遗症。 19具有AD的冲浪者，考虑种族和性别差异，并随着时间的流逝而遵循这些变化；和4） 研究肿瘤坏死因子（TNF）阻滞剂对总体死亡率和长途肿瘤的治疗作用 AD的COVID-19中表面上的Neuro-PASC。为了回答这些问题，我们将利用美国在全国范围内实现的 8000万患者的去识别电子健康记录（EHR）的时间数据库（确认了480万 2019冠状病毒病病例）。我们的研究将主要关注超过1700万的高级患者³65岁，包括 超过100万例19例，有265,818例被诊断为AD的患者，两者都有22,518例患者 Covid-19和AD（截至2021年5月20日）。我们的研究将建立用于实时分析EHR的方法 全美脆弱的衰老人口在检查传染病及其 与现有疾病（例如AD）的互动，如果另一个疾病，这将使我们能够更好地做好准备 大流行超越了我们。因此，这些研究的意义超出了手头的数据。